Company
Headquarters: Dijon, France
Employees: 85
CEO: Mr. Patrick Alexandre
€195.9 Million
EUR as of Jan. 1, 2024
US$216.3 Million
Company | Market Cap (USD) |
---|---|
Intuitive Surgical, Inc. | $113.81 B |
EssilorLuxottica SA | $90.57 B |
Becton, Dickinson and Company | $70.33 B |
HOYA Corp | $43.39 B |
Alcon Inc. | $37.65 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Top 1-year algo backtest: +287.69%
$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Crossject SA has the following listings and related stock indices.
Stock: Euronext: ALCJ wb_incandescent
Stock: FSX: 74C wb_incandescent